CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans

Infection and Immunity

Volumn 77, Issue 9, 2009, Pages 4168-4176

  Meoni, Eva ^a   Faenzi, Elisa ^a   Frigimelica, Elisabetta ^a   Zedda, Luisanna ^a   Skibinski, David ^a   Giovinazzi, Serena ^a   Bonci, Alessandra ^a   Petracca, Roberto ^a   Bartolini, Erika ^a   Galli, Giuliano ^a   Agnusdei, Mauro ^a   Nardelli, Filomena ^a   Buricchi, Francesca ^a   Norais, Nathalie ^a   Ferlenghi, Ilaria ^a   Donati, Manuela ^b   Cevenini, Roberto ^b   Finco, Oretta ^a   Grandi, Guido ^a   Grifantini, Renata ^a,c  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Externautics SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN CT043; PROTOZOAL PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; LUNG INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SEQUENCE ANALYSIS; TH1 CELL;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA MURIDARUM; CHLAMYDIA TRACHOMATIS; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; IMMUNIZATION; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; PORINS; TH1 CELLS;

EID: 69049117338     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00344-09     Document Type: Article

References (47)

1. Alexandrenne, C., A. Wijkhuisen, F. Dkhissi, V. Hanoux, C. Créminon, D. Boquet, and J. Y. Couraud. 2009. Generating antibodies against the native form of the human prion protein (hPrP) in wild-type animals: a comparison between DNA and protein immunizations. J. Immunol. Methods 341:41-49.
2. Brunham, R. C., and J. Rey-Ladino. 2005. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat. Rev. Immunol. 5:149-161.
3. Caldwell, H. D., J. Kromhout, and J. Schachter. 1981. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect. Immun. 31:1161-1176.
4. Coligan, J. E., A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (ed.). 1994. Current protocols in immunology, unit 7.1. Wiley & Sons, Inc., New York, NY.
5. Cristillo, A. D., S. Wang, M. S. Caskey, T. Unangst, L. Hocker, L. He, L. Hudacik, S. Whitney, T. Keen, T. H. Cho, S. Shen, S. Joshi, V. S. Kalyanaraman, B. Nair, P. Markham, S. Lu, and R. Pal. 2006. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 346:151-168.
6. De la Maza, L. M., and E. M. Peterson. 2002. Vaccines for Chlamydia trachomatis infections. Curr. Opin. Investig. Drugs 3:980-986.
7. DeVinney, R., A. Gauthier, A. Abe, and B. B. Finlay. 1999. Enteropathogenic Escherichia coli: a pathogen that inserts its own receptor into host cells. Cell. Mol. Life Sci. 55:961-976.
8. Dong-Ji, Z., X. Yang, C. Shen, H. Lu, A. Murdin, and R. C. Brunham. 2000. Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th1 cellular immune responses. Infect. Immun. 68:3074-3078.
9. Dreses-Werringloer, U., I. Padubrin, B. Jurgens-Saathoff, A. P. Hudson, H. Zeidler, and L. Köhler. 2000. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob. Agents Chemother. 44:3288-3297.
10. Finco, O., A. Bonci, M. Agnusdei, M. Scarselli, R. Petracca, N. Norais, G. Ferrari, I. Garaguso, M. Donati, V. Sambri, R. Cevenini, G. Ratti, and G. Grandi. 2005. Identification of new potential vaccine candidates against Chlamydia pneumoniae by multiple screenings. Vaccine 23:1178-1188.
11. Follmann, F., A. W. Olsen, K. T. Jensen, P. R. Hansen, P. Andersen, and M. Theisen. 2008. Antigenic profiling of a Chlamydia trachomatis gene-expression library. J. Infect. Dis. 197:897-905.
12. Grifantini, R., O. Finco, E. Bartolini, M. Draghi, G. Del Giudice, C. Kocken, A. Thomas, S. Abrignani, and G. Grandi. 1998. Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid. Eur. J. Immunol. 28:1225-1232.
13. Hafner, L. M., and C. McNeilly. 2008. Vaccines for Chlamydia infections of the female genital tract. Future Microbiol. 3:67-77.
14. Igietseme, J. 2004. Towards a Chlamydia vaccine. Expert Rev. Vaccines 3:237-242.
15. Kim, S. K., and R. De Mars. 2001. Epitope clusters in the major outer membrane protein of Chlamydia trachomatis. Curr. Opin. Immunol. 13:429-436.
16. Koskela, P., T. Anttila, A. Bjorge, A. Brunsvig, J. Dillner, M. Hakama, T. Hakulinen, E. Jellum, M. Lehtinen, P. Lenner, T. Luostarinen, E. Pukkala, P. Saikku, S. Thoresen, L. Youngman, and J. Paavonen. 2000. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int. J. Cancer 85:35-39.
17. Lan, J., J. M. M. Walboomers, R. Roosendaal, G. J. J. van Doornum, D. M. MacLaren, C. J. L. M. Meijer, and A. J. C. van den Brule. 1993. Direct detection and genotyping of Chlamydia trachomatis in cervical scrapes by using polymerase chain reaction and restriction fragment length polymorphism analysis. J. Clin. Microbiol. 31:1060-1065.
18. Ludtke, S. J., P. R. Baldwin, and W. Chiu. 1999. EMAN: semiautomated software for high resolution single-particle reconstruction. J. Struct. Biol. 128:82-97.
19. McCluskie, M. J., and H. L. Davis. 1998. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161:4463- 4466.
20. McMahon, J. M., E. Signori, K. E. Wells, V. M. Fazio, and D. J. Wells. 2001. Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase - increased expression with reduced muscle damage. Gene Ther. 8:1264-1270.
21. Montigiani, S., F. Falugi, M. Scarselli, O. Finco, R. Petracca, G. Galli, M. Mariani, R. Manetti, M. Agnusdei, R. Cevenini, M. Donati, R. Nogarotto, N. Norais, I. Garaguso, S. Nuti, G. Saletti, D. Rosa, G. Ratti, and G. Grandi. 2002. Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect. Immun. 70:368-379.
22. Moore, T., G. A. Ananaba, J. Bolier, S. Bowers, T. Belay, F. O. Eko, and J. U. Igietseme. 2002. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology 105:213-221.
23. Morrison, S. G., and R. P. Morrison. 2005. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J. Immunol. 175:7536-7542.
24. Murdin, A. D., and R. C. Brunham. 2004. Vaccines for Chlamydia trachomatis and Chlamydia pneumoniae, p. 835-846. In M. M. Levine, J. B. Kaper, R. Rappuoli, M. A. Liu, and M. F. Good (ed.), New generation vaccines, 3rd ed. Marcel Dekker, Inc., New York, NY.
25. Olsen, A. W., F. Follmann, K. Jensen, P. Højrup, R. Leah, H. Sørensen, S. Hoffmann, P. Andersen, and M. Theisen. 2006. Identification of CT521 as a frequent target of Th1 cells in patients with urogenital Chlamydia trachomatis infection. J. Infect. Dis. 194:1258-1266.
26. Pal, R., V. S. Kalyanaraman, B. C. Nair, S. Whitney, T. Keen, L. Hocker, L. Hudacik, N. Rose, I. Mboudjeka, S. Shen, T. H. Wu-Chou, D. Montefiori, J. Mascola, P. Markham, and S. Lu. 2006. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 348:341-353.
27. Pal, S., I. Theodor, E. M. Peterson, and L. M. de la Maza. 2001. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect. Immun. 69:6240-6247.
28. Plummer, F. A., J. N. Simonsen, D. W. Cameron, J. Ndinya-Achola, O. Ndinya-Achola, J. K. Kreiss, M. N. Gakinya, P. Waiyaki, M. Cheang, P. Piot, A. R. Ronald, and E. N. Ngugi. 1991. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J. Infect. Dis. 163:233-239.
29. Rank, R. G., L. S. F. Soderberg, and A. L. Barron. 1985. Chronic chlamydial genital infection in congenitally athymic nude mice. Infect. Immun. 48:847-849.
30. Rodríguez-Ortega, M. J., N. Norais, G. Bensi, S. Liberatori, S. Capo, M. Mora, M. Scarselli, F. Doro, G. Ferrari, I. Garaguso, T. Maggi, A. Neumann, A. Couvre, J. L. Terford, and G. Grandi. 2006. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat. Biotechnol. 24:191-197.
31. Ryan, E. J., E. McNeela, M. Pizza, R. Rappuoli, L. O'Neill, and K. H. Mills. 2000. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. J. Immunol. 165:5750-5759.
32. Schirmbeck, R., and J. Reimann. 2001. Revealing the potential of DNA-based vaccination: lessons learned from the hepatitis B virus surface antigen. Biol. Chem. 382:543-552.
33. Seder, R. A., and A. V. Hill. 2000. Vaccines against intracellular infections requiring cellular immunity. Nature 406:793-798.
34. Somani, J., V. B. Bhullar, K. A. Workowski, C. E. Farshy, and C. M. Black. 2000. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J. Infect. Dis. 181:1421-1427.
35. Stephens, R. S. (ed.). 1999. Chlamydia: intracellular biology, pathogenesis and immunity. ASM Press, Washington, DC.
36. + T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract. Infect. Immun. 63:3302-3308.
37. Szekeres-Bartho, J., A. Barakony, G. Par, B. Polgar, T. Palkovics, and L. Szereday. 2001. Progesterone as an immunomodulatory molecule. Int. Immunopharmacol. 1:1037-1048.
38. Tang, D.C., M. DeVit, and S. A. Johnston. 1992. Genetic immunization is a simple method for eliciting an immune response. Nature 356:152-154.
39. Tanghe, A., J. Content, J.-P. Van Vooren, F. Portaels, and K. Huygen. 2001. Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect. Immun. 69:5403-5411.
40. Tanzer, R. J., and T. P. Hatch. 2001. Characterization of outer membrane proteins in Chlamydia trachomatis LGV serovar L2. J. Bacteriol. 183:2686-2690.
41. Tuffrey, M., P. Falder, and D. Taylor-Robinson. 1986. Salpingitis in mice induced by human strains of Chlamydia trachomatis. Br. J. Exp. Pathol. 67:605-616.
42. Van Voorhis, W. C., L. K. Barrett, Y. T. Cosgrove Sweeney, C. C. Kuo, and D. L. Patton. 1996. Analysis of lymphocyte phenotype and cytokine activity in the inflammatory infiltrates of the upper genital tract of female macaques infected with Chlamydia trachomatis. J. Infect. Dis. 174:647-650.
43. Van Voorhis, W. C., L. K. Barrett, Y. T. Cosgrove Sweeney, C.-C. Kuo, and D. L. Patton. 1997. Repeated Chlamydia trachomatis infection of Macaca nemestrina fallopian tubes produces a Th1-like cytokine response associated with fibrosis and scarring. Infect. Immun. 65:2175-2182.
44. Ward, M. E. 1995. The immunobiology and immunopathology of chlamydial infections. APMIS 103:769-796.
45. WHO. 2001. Global prevalence and incidence of selected curable sexually transmitted diseases. World Health Organization report, p. 10-13. WHO, Geneva, Switzerland.
46. Widera, G., M. Austin, D. Rabussay, C. Goldbeck, S. W. Barnett, M. Chen, L. Leung, G. R. Otten, K. Thudium, M. J. Selby, and J. B. Ulmer. 2000. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol. 164:4635-4640.
47. Wyrick, P. B., and S. T. Knight. 2004. Pre-exposure of infected human endometrial epithelial cells to penicillin in vitro renders Chlamydia trachomatis refractory to azithromycin. J. Antimicrob. Chemother. 54:79-85.